Alphatec Holdings Price Target Cut to $14 After Revenue Miss
ATEC•Needham cut Alphatec Holdings’ price target from $25 to $14, still implying 95.5% upside potential. Q1 results showed break-even EPS against a $0.01 loss estimate and $192.11 million in revenues, which missed forecasts, driving a 29.86% share decline after a 1.2 million-share fund sale.
1. Price Target Revision
A Needham analyst cut Alphatec Holdings’ price target from $25 to $14, indicating 95.5% upside potential from current levels. The reduction reflects a cautious near-term outlook on the medical technology company’s growth prospects.
2. Q1 Financial Performance
In the first quarter Alphatec reported break-even EPS compared with an estimated $0.01 loss, marking significant improvement from a $0.23 per share loss a year earlier. Revenues reached $192.11 million but fell short of analyst forecasts, highlighting challenges in sales growth.
3. Share Decline and Fund Sale
Alphatec stock slid 29.86% in response to the revenue shortfall and earnings update. The decline accelerated after a fund sold 1.2 million shares, raising concerns over shareholder confidence and potential further volatility.
